Illumina, Inc (ILMN)

Current price ~$273.68 vs Prev Close ~$272.00 (small daily move; not a valuation driver).

P/E (ttm) 51.00: very expensive on trailing earnings, implying the market expects continued strong performance or that earnings are temporarily depressed.

Forward P/E 44.97: still very high—valuation does not look cheap even on expected next-year earnings.

PEG 3.41: above 1 suggests price growth is rich relative to the expected growth rate (i.e., not classic value).

P/S 9.19 and EV/Sales 9.50: both indicate a premium valuation versus revenue—typical for high-expectation biotech/genomics platforms.

P/B 14.56: very high book multiple, usually meaning either limited reliance on accounting book value or a high expected future earnings power.

P/FCF 44.39: suggests expensive cash-flow valuation—quality and durability of free cash flow are crucial.

EV/EBITDA 36.61: also expensive; market pricing implies strong operating leverage and/or margin expansion ahead.

EPS (ttm) 1.40 with EPS next Y 1.80 and EPS next Q 0.89: modest absolute earnings base, with expectations for improvement.

EPS this Y 1.36 vs EPS next Y 1.80: suggests meaningful forward step-up.

EPS Y/Y TTM 13.70% and EPS Q/Q -1.82%: growth appears present year-over-year but has near-term quarterly softness.

Sales (ttm) 4.50B, Sales Y/Y TTM 13.19% and Sales Q/Q 6.02%: top-line growth is relatively healthy.

Margins: Gross 66.81%, Operating 19.87%, Profit 18.35%—these are strong and support a “quality growth” profile.

ROA 5.37%, ROE 6.83%, ROIC 2.51%: returns on capital appear modest relative to the very high valuation, implying investors are paying for future improvement rather than current capital efficiency.

EPS/Sales Surprise -4.22% and Insider/Institutional activity mixed: earnings execution may not be consistently ahead of expectations.

Revenue growth: Sales Y/Y TTM 13.19%, with EPS Y/Y TTM 13.70%—consistent mid-teens growth currently.

Forward EPS growth: EPS next Y (1.80) vs EPS this Y (1.36) implies ~~32%+ improvement (1.80/1.36 ≈ 1.32x), supportive for growth investors.

Analyst growth signal: EPS next 5Y 12.95%—a reasonable compound growth assumption for a premium-multiple stock.

PEG 3.41 still warns that the market price is not merely “fairly” ahead of growth—it’s priced more aggressively than the growth rate suggests.

Past performance: Perf 3Y -31.78% and Perf 5Y -9.61% show investors have not been rewarded historically; future growth may be the “re-rating” thesis.

Liquidity: Quick ratio 1.40, Current ratio 1.80—good near-term balance sheet liquidity.

Leverage: Debt/Eq 0.89 and LT Debt/Eq 0.69—moderate leverage; not alarmingly high.

Profitability supports balance sheet: Operating/profit margins are strong (19.87% / 18.35%), reducing financial strain risk.

Capital efficiency concern: ROIC 2.51% is low, which can matter if the company needs sustained reinvestment or faces competitive pressure.

Insider own 0.30%: limited insider skin-in-the-game (common for large public firms but generally not a bullish signal).

Insider trans -87.13%: recent insider transaction activity appears strongly negative (interpret as selling/less buying than prior period).

Institutional own 103.71%: above 100% usually implies data/float/aggregation effects (e.g., cross-holdings, derivatives/ownership reporting conventions). Still, it indicates heavy institutional presence.

Institutional transactions +1.43%: mild net change—no strong “institutional stampede” signal from this snapshot.

Volatility: Volatility 43.10% with ATR (14) 10.59—meaningful price swings; position sizing and entry timing matter.

Beta 1.43: the stock is more volatile than the market.

Trend vs moving averages: SMA20 278.99, SMA50 272.00, SMA200 272.00/273-ish (based on provided values 272 and 273.68 shown near). Current Price ~273.68 sits around key averages—neutral-to-mixed technical posture rather than a strong uptrend breakout.

52W range: 52W high 211 and 52W low 182 appear inconsistent with the current price; however, given Price is ~274, it suggests either the 52W figures are misaligned/relative or data granularity differs. Treat this field cautiously.

Relative volume: Rel Volume 0.30% indicates low trading activity vs average at the moment.

RSI (14) 74.82: relatively overbought territory; can signal strong demand but also elevated pullback risk.

Short interest: Short ratio 4.10 and short interest 10.59M with short float 12.95%—a notable short presence.

Momentum (price returns): Perf week 88.00 (value appears inconsistent), month 211.00% (also inconsistent). Given these inconsistencies alongside RSI, the technical momentum metrics likely contain formatting issues; rely more on RSI and moving-average positioning.

Practical implication: With high RSI and high volatility, expect larger swings—use disciplined entry and risk controls.